Jason J. Luke, MD, on Melanoma: KEYNOTE-716 Trial of Pembrolizumab vs Placebo

September 19, 2021 By The ASCO Post Staff

Jason J. Luke, MD, of UPMC Hillman Cancer Center, discusses phase III results showing that adjuvant pembrolizumab for patients with resected stage IIB and IIC melanoma decreased the risk of disease recurrence or death by 35% compared with placebo. It was also associated with significantly prolonged recurrence-free survival (Abstract LBA3).

Related Content